perhaps ameliorate the progress of ARF in patients with acute oliguria is strong. The evidence for this Background. Studies on the role of loop diuretics in patients with acute renal failure (ARF ) are largely practice is poor. Most reported studies have been largely anecdotal, retrospective, non randomized or retrospective, anecdotal, and poorly controlled. We report the results of a prospective, randomized, uncontrolled [1][2][3][4][5][6][7][8][9].
Introduction

Patient selection
In clinical practice the temptation to use high doses of loop diuretics to increase urine flow rate and thereby reversible acute intrinsic renal failure as defined by a rise in estimated body weight per dose. If the serum creatinine fell thereafter the dose of study drug was decreased from 3 mg/kg serum creatinine to over 180 mmol/l (2.03 mg/dl ).
When first assessed each patient had bladder catheter to 2 mg/kg, to 1 mg/kg, and finally stopped as renal function recovered. Both the study drug and dopamine were continued drainage established and attempts were made to correct all reversible prerenal factors. A central venous catheter or if the patient became dialysis dependent or failed to recover renal function, for a maximum of 21 days, or until death pulmonary artery catheter was inserted, arterial blood gases were measured and pulse oximetry established. Obstructive within 21 days. Although the study ended at day 21 the survivors have continued on long-term follow up. uropathy was excluded by ultrasonography.
Those patients whose ARF did not respond to correction Mannitol was discontinued before day 3 if the patient remained severely oliguric or anuric or became hyperosmolar of prerenal factors and who were not obstructed were then considered for enrolment into the study. Exclusion criteria (measured osmolality-calculated osmolality>17). are listed in Table 1 . Written consent for the study was obtained either from the patient or, if unconscious, from the Statistical analysis next of kin, after explaining the various options and risks. The protocol was approved the Ethics committee of Glasgow A sample size of 90 was determined to be sufficient to detect Royal Infirmary. a clinically significant difference in outcome between the three groups. The absolute values of the primary variables (recovery, death, or dialysis) were compared using chiMethods squared analysis. Other variables were analysed by means of analysis of variance (ANOVA). Patients were enrolled into the study at time (t)=0, after a run-in period of a minimum of 2 h. During this time two consecutive baseline hourly urine collections were made and a blood sample taken. Urine flow rate (ml/h), creatinine Results clearance (ml/min), and fractional excretion of sodium were calculated. In addition, the serum concentrations of sodium, A total of 278 oliguric patients were assessed for entry potassium, calcium, C reactive protein (CRP) and c glutamyl into the study, 25% of whom recovered with adequate transferase (cGT ) were measured. An APACHE II score was rehydration. A further 40% were excluded as they did calculated for each patient during the run-in period [12] . not fit the entry criteria or refused consent. The Serum biochemistry was repeated at t=24 h and thereafter on a daily basis at 0800 hours until day 21 or, if sooner, remaining patients (n=96) were enrolled into the death. In addition, serum osmolality was measured for the study. Of these, four patients are excluded from the first 3 days while mannitol was being used. This value was statistical analysis; two died in the run-in phase before compared with that obtained by calculating the serum the study drug was given, and a further two patients osmolality using the formula:
were inappropriately enrolled as they had been in another study within the preceding 30 days. Ninety-(1.86×serum sodium)+urea+glucose in+9 [13] . two patients are therefore available for analysis on an Urine was collected every 6 h for the first 48 h and thereafter intention to treat basis. The sample size for each group every 24 h. Hourly urine flow rates were calculated. is as follows: torasemide n=30, frusemide n=32, and
Creatinine clearance and fractional excretion of sodium were placebo n=30. calculated as before. Table 2 shows demographic and clinical features. Patients in each of the groups were well matched for Treatment age, sex, severity of illness, and degree of renal impairment. The causes of acute renal failure were similar in All patients were given dopamine (continuous infusion of all three groups and have been amalgamated. In 48% 2 mg/kg estimated body weight/min) and mannitol (infusion ARF occurred in association with overwhelming infecof 100 ml of a 20% solution for 1 h every 6 h for a maximum of 3 days), and were randomized to receive either frusemide, tion. In 15% ARF was preceded by surgery for an torasemide, or placebo as an intravenous infusion over 1 h abdominal aortic aneurysm. The remainder were due every 6 h for up to 21 days. A previous study suggested that to a number of causes including rhabdomyolysis, haein chronic renal failure, when given intravenously, torasemide is equipotent to frusemide [14] . This study has made the assumption that this holds for ARF. The study drug was molytic-uraemic syndrome, acute liver failure, and (torasemide day 6.9±6.8, frusemide day 4.5±5, placebo day 7.6±6.7, P=0.46). drug toxicity.
Actuarial survival curves for the three groups are shown in Figure 1 . This is continued up to day 56, Loop diuretic (torasemide or frusemide) vs placebo since all of the patients who died as a result of their Table 3 shows the outcome of treatment with loop primary illness had done so by then. At day 56 survival diuretic or placebo. Patients given torasemide or fruse-between placebo (43%), frusemide(38%), and torasemmide had a significant increase in urine output and ide (30%) was not significantly different. fractional excretion of sodium in the first 24 h comDaily median values for serum creatinine, sodium, pared to placebo. These patients did not receive any potassium, calcium and CRP over the 21-day study more mannitol than those in the placebo group. period were calculated. There was no significant differHowever, there was no significant difference in the ence in these between the three groups. final outcome (recovery, dialysis, or death) at day 21. Twenty three per cent of placebo patients recovered full renal function without requiring haemodialysis Oliguric vs non-oliguric patients compared to 17% and 28% for patients given torasemide and frusemide respectively (P=0.56).
The patients were divided into two groups-oliguric The proportion of patients requiring dialysis were and non-oliguric-based on their urine output during not different in the three groups. The time to dialysis the first 24 h after starting medication. Those patients in each group was torasemide 5±5 days, frusemide whose urine volume in the first 24 h averagedÁ50 ml/h 5.4±5.7 days, and placebo 2.8±1.2 days (P=0.35). were termed non-oliguric. Conversely those patients Loop diuretics had no effect on the duration of dialysis with hourly urine volumes<50 ml/h were termed olig-(torasemide 5.6±4 days, frusemide 13.4±13.7 days, uric. One patient has been excluded from statistical placebo 13.2±10.7 days, P=0.16).
analysis because he died prior to the first urine collecThe number of patients who died by day 21 without tion after entry into the study. Therefore n=91. requiring dialysis was 47% and 41% in the torasemide Fifty-one patients remained oliguric during the first and frusemide groups respectively and 37% in the 24 h of the study while 40 were non-oliguric either placebo group (P=0.73). The total number of deaths spontaneously or because of diuretic treatment. By day by day 21 (dialysis and non-dialysis dependent patients) fifty-six, 35 (69%) of the oliguric patients had died was 70% in the torasemide group, 66% in the frusemide compared to 17 (43%) of the non-oliguric patients group and 50% in the placebo group (P=0.24).
(P=0.01). The pre-study APACHE II score was better Table 4 shows the final outcome of all patients who in the group who became non-oliguric (17.2±5.9 vs required dialysis. There was no significant difference 20.6±5.5, P=0.008), as was the pre-study creatinine between the groups. All patients still alive at day 56 clearance (14±11 ml/min vs 4±4 ml/min, P<0.0001). were no longer dialysis-dependent.
In the group of patients who were non-oliguric, 8 The day the serum creatinine started to fall spontan-(20%) were on placebo and 32 (80%) were on a eously was taken as an indication of renal recovery diuretic. In the non-oliguric placebo group (n=8) two and there is no significant difference between the groups patients (25%) had died by day 56. In the non-oliguric diuretic group (n=32), 15 (47%) had died by day 56 
Side-effects
There was a non-significant increase in the incidence Torasemide caused a significant rise in cGT, an effect that is reversible and given as a warning on the *Chi-square test, placebo vs torasemide or frusemide.
international data sheet.
Only 22% of patients continued on mannitol for 3 days. The reasons for stopping mannitol are as follows: Table 4 . Final outcome (day 56) of patients requiring dialysis severe oliguria/anuria (n=27), death before day 3 (n=24), hyperosmolality (n=15), acute pulmonary
oedema (n=1), renal recovery (n=2), withdrawn from study (n=2). The patient who developed pulmonary oedema was not hyperosmolar. Only one of the patients Death 64 60 42 who became hyperosmolar had any symptoms (confusion).
*Chi-square test, placebo vs frusemide or torasemide, P=0.52. diuresis in 22% of 104 patients given a variable does The use of high-dose loop diuretics in patients with (40-500 mg) of frusemide. Other groups however, have incipient ARF can significantly improve urine output. shown that intravenous frusemide modifies ARF by Thus 57% of patients given torasemide and 48% of causing sustained polyuria [3] [4] [5] [6] [7] [8] [9] . patients given frusemide had a significant increase in urine volume in the first 24 h compared to placebo Can loop diuretics shorten the period of renal (23%).
dysfunction and reduce the need for dialysis Patients who became non-oliguric had a lower mortality than those patients who remained oliguric (43% Renal recovery was considered to begin when the vs 69% P=0.01). However, patients who became non-serum creatinine started to fall spontaneously, without oliguric were less ill as evidenced by a significantly dialysis. There was no significant difference in the time lower APACHE II score. They may also have had less to renal recovery between the three groups. The need severe renal failure as their creatinine clearance was for dialysis was also not different. These findings higher. However, this is an imprecise measurement of agree with the studies of Brown et al. [5] and renal function in these patients. On this evidence we Borirakchanyavat et al. [9] . cannot attribute a 'beneficial' effect on mortality solely Minuth and colleagues [2] , however, found a reducto the use of loop diuretics. tion in the need for dialysis in patients given loop Of more significance would have been a significant diuretic. Cantarovich et al. [3] showed that a progressimprovement in mortality between those patients who ive doses of frusemide (100-3200mg/day in geometric became spontaneously non-oliguric with placebo and progression on continuous days) shortened the period those whose diuresis was induced by the use of loop of renal dysfunction, presumably because of the high diuretics. There was no difference in mortality at day average daily dose of frusemide (1.24 g/day) received 56 between the non-oliguric group who had placebo by the progressive dose group compared to the fixed (spontaneously non-oliguric) and the non-oliguric dose group (600 mg/day). We gave a maximum dose group given loop diuretic. However, the number of of loop diuretic 1.2 g/day. patients in this subgroup analysis is small and larger numbers of patients are required for statistical analysis.
Can loop diuretics decrease mortality in ARF?
It has been suggested that continuous low-dose infusions of frusemide might be preferable to high-Our prospective randomized double-blind study failed to demonstrate an improved mortality in patients dose bolus injections [15] . It is possible, therefore, that we might have achieved an even greater diuretic effect treated with loop diuretics, a finding in keeping with most previous less well-controlled studies. [1, 2, 5, 6 ] . by the continuous infusion of the loop diuretic.
In 1976 Kleinknecht et al.
[1] studied 55 patients Only Anderson et al. [8] showed a reduction in mortality in the subgroup of patients given frusemide and with established oliguric ARF. Thirty-three were given
